Compugen is a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery
Unigen™ is Compugen’s code-to-cure, flexible-loop platform for the computational prediction of novel drug target discovery and development of cancer immunotherapy. Unigen™ combines Compugen’s deep scientific knowledge, AI/ML predictive algorithms and a cloud-based, technology-agnostic platform integrating a variety of biological data such as multi-omics, single cell RNA sequencing and spatial omics data. The outcomes from the preclinical and clinical trials enrich the proprietary knowledgebase to discover additional novel drug targets and further understand complex biology.
To date, Unigen™ has yielded multiple novel immuno-oncology drug targets, potential first or best-in-class clinical stage immuno-oncology programs, validating partnerships with multiple pharmaceutical companies and undisclosed programs in its early-stage pipeline.